All In Biotech

Drug Trial Radar · NCT03049189

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

324

Actual

Start

Feb 2, 2017

Primary completion

Nov 27, 2024

Study completion Nov 2029

Sponsor

Lead sponsor
ITM Solucin GmbHIndustry
Sponsor type
Industry
Collaborators
ABX CRO; PSI CRO
First posted
Feb 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Conditions

  • Neuroendocrine Tumors

Interventions

  • 177Lu-edotreotide PRRTDrug

    PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.

  • EverolimusDrug

    Everolimus will be administered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.

  • Amino-Acid SolutionOther

    The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From date of randomization until the date of first documented progression or death, assessed up to 30 months,

Locations

52 sites in 14 countries. Site status is shown where the registry gives one.

  • Banner Health d.b.a. Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Stanford University

    Stanford, California

  • Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Excel Diagnostics & Nuclear Oncology Center

    Houston, Texas

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Olivia Newton-John Cancer & Wellness Centre, Austin Hospital

    Heidelberg, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Allgemeines Krankenhaus Wien

    Vienna, Austria

  • Institut Jules Bordet

    Brussels, Belgium

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

  • University Hospital Olomouc

    Olomouc, Czechia

  • University Hospital Motol

    Prague, Czechia

  • Hospices civils de Lyon

    Bron, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • HP Hôpital Beaujon

    Clichy, France

  • Institut de Recherche en Cancérologie de Montpellier (IRCM)

    Montpellier, France

  • CHU de Nantes - Hôtel Dieu

    Nantes, France

  • IUCT-Oncopole

    Toulouse, France

  • Zentralklinik Bad Berka GmbH

    Bad Berka, Germany

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • University Medical Center, Abteilung für Nuklearmedizin

    Hamburg, Germany

  • Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke Universität

    Magdeburg, Germany

  • Philipps Universität Marburg

    Marburg, Germany

  • Klinikum rechts der Isar Technische Universität München

    Munich, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl

    Meldola, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • European Institute of Oncology (EIO)

    Milan, Italy

  • Academic Medical Center, University of Amsterdam

    Amsterdam, Netherlands

  • MSC Memorial Cancer Centre

    Gliwice, Poland

  • "Gammed" Izabela Chuchrowksa

    Warsaw, Poland

  • University Cape Town (UCT), Groote Schuur Hospital

    Cape Town, South Africa

  • University of Pretoria & Steve Biko Academic Hospital

    Pretoria, South Africa

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.